CN114869877B - Small molecule compound and application thereof as LAG3 protein inhibitor - Google Patents
Small molecule compound and application thereof as LAG3 protein inhibitor Download PDFInfo
- Publication number
- CN114869877B CN114869877B CN202210096008.7A CN202210096008A CN114869877B CN 114869877 B CN114869877 B CN 114869877B CN 202210096008 A CN202210096008 A CN 202210096008A CN 114869877 B CN114869877 B CN 114869877B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- protein
- lag3
- hexamethoxyflavanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000017578 LAG3 Human genes 0.000 title claims abstract description 30
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 title claims abstract description 24
- 229940121649 protein inhibitor Drugs 0.000 title claims abstract description 7
- 239000012268 protein inhibitor Substances 0.000 title claims abstract description 7
- -1 Small molecule compound Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- ZDLYNMZEAFURQY-UHFFFAOYSA-N 5,6,7,8,3',4'-Hexamethoxyflavone Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 ZDLYNMZEAFURQY-UHFFFAOYSA-N 0.000 claims 2
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims 2
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- LTRBUBSPQISFFL-UHFFFAOYSA-N Citromitin Chemical compound C1=C(OC)C(OC)=CC=C1C1OC2=C(OC)C(OC)=C(OC)C(OC)=C2C(=O)C1 LTRBUBSPQISFFL-UHFFFAOYSA-N 0.000 abstract description 22
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 101150030213 Lag3 gene Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229940125563 LAG3 inhibitor Drugs 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100038664 Fibrinogen-like protein 1 Human genes 0.000 description 2
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application field of small organic molecule compounds, in particular to a small molecule compound and application thereof as LAG3 protein inhibitor. The compound 5,6,7,8,3',4' -hexamethoxyflavanone can inhibit the combination of LAG3 protein and MHC II protein, and the IC 50 value is 1.54 mu M, so that the compound can be used for treating tumors, and a new idea is provided for developing novel anticancer drugs.
Description
Technical Field
The invention relates to the application field of small organic molecule compounds, in particular to a small molecule compound and application thereof as LAG3 protein inhibitor.
Background
Lymphocyte activation gene 3 (LAG-3 or CD 223) is a type I transmembrane protein, an inhibitory receptor within a targeted tumor microenvironment that is expressed on the cell surface of activated cd4+ and cd8+ T cells and a subset of NK and dendritic cells, which upon activation by its ligand can inhibit proliferation, activation, effector function and homeostasis of CD4 and CD 8T cells, promoting immune escape of tumor cells. LAG-3 is closely related to CD4, while CD4 is a T helper activated accessory receptor. Both molecules have 4 extracellular Ig-like domains and need to bind their ligands (major histocompatibility complex (MHC) class II) to exert their functional activity. Unlike CD4, LAG-3 is expressed only on the cell surface of activated T cells, and its cleavage from the cell surface terminates LAG-3 signaling. FGL1 is a liver secreted protein, a major LAG-3 functional ligand independent of MHC-II.
Patent CN110720039a discloses a method of treating a tumor in a human patient, the method comprising (i) identifying the patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a PD1 pathway inhibitor and immune checkpoint inhibitor combination, a LAG-3 inhibitor and PD-1 pathway inhibitor combination, or an anti-CTLA 4 antibody. Patent CN113825527a discloses a method for treating or inhibiting the growth of cancer, comprising selecting a patient suffering from cancer and administering a therapeutically effective amount of a LAG-3 inhibitor in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In certain embodiments, administration of the PD-1 inhibitor enhances the efficacy of the LAG-3 inhibitor (e.g., an anti-LAG-3 antibody or antigen-binding fragment thereof) in inhibiting cancer growth. The medicine taking LAG-3 as a target spot mainly treats cancers and autoimmune diseases, is an immune escape mechanism and has guiding significance for the design of cancer immunotherapy. However, no document currently discloses that the compound 5,6,7,8,3',4' -hexamethoxyflavanone is capable of inhibiting LAG3 protein binding to MHC ii protein or LAG3 protein binding to FGL1 protein. Therefore, developing a small molecule inhibitor for inhibiting the combination of LAG3 and MHC-II can provide a new idea for cancer immunotherapy and improve the cure rate of cancer.
Disclosure of Invention
In view of the above problems and the deficiencies of the prior art, it is a primary object of the present invention to provide the use of the compound 5,6,7,8,3',4' -hexamethoxyflavanone as LAG3 protein inhibitor.
Preferably, the compound 5,6,7,8,3',4' -hexamethoxyflavanone inhibits LAG3 protein binding to MHC ii proteins.
The second object of the invention is to provide the application of the compound 5,6,7,8,3',4' -hexamethoxyflavanone in preparing the medicine for treating LAG3 positive tumor, wherein the structural formula of the compound is shown as the formula (I):
The third object of the invention is to provide application of 5,6,7,8,3',4' -hexamethoxyflavanone in preparing medicines for preventing LAG3 positive tumors, wherein the structural formula of the compound is shown as formula (I):
Preferably, the tumor is a malignancy selected from the group consisting of liver cancer, bone cancer, pancreatic cancer, skin cancer, oral cancer, head or neck cancer, breast cancer, lung cancer, skin or intraocular malignant melanoma, kidney cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, anal region cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, non-hodgkin's lymphoma, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urinary tract cancer, penile cancer, childhood cancer, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal pelvis cancer, central nervous system tumor, primary CNS lymphoma, tumor angiogenesis, spinal cord axis tumor, brain stem glioma, pituitary adenoma, kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, environmental carcinoma, hematological malignancy, examples include multiple myeloma, B-cell lymphoma, hodgkin's lymphoma/primary mediastinal B-cell lymphoma, non-hodgkin's lymphoma, acute myeloid lymphoma, chronic myelogenous leukemia, chronic lymphoid leukemia, follicular lymphoma, diffuse large B-cell lymphoma, burkitt's lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, mycosis fungoides, degenerative large cell lymphoma, T-cell lymphoma, and precursor T-lymphoblastic lymphoma, and any combination thereof.
Preferably, the compound 5,6,7,8,3',4' -hexamethoxyflavanone treats or prevents tumors by inhibiting LAG3 protein binding to MHC ii proteins.
Preferably, the compound 5,6,7,8,3',4' -hexamethoxyflavanone is added with pharmaceutically acceptable carriers and/or auxiliary materials to be prepared into any one of tablets, sprays, granules, capsules, oral liquid, injection and suspension.
The beneficial effects of the invention are as follows: the invention selects the compound 5,6,7,8,3',4' -hexamethoxyflavanone as the active ingredient of the inhibitor, can effectively inhibit the combination of LAG3 protein and MHC II protein, further treat tumors, and also provides a new idea for developing novel anticancer drugs.
Drawings
FIG. 1 inhibitory Effect of Compounds 5,6,7,8,3',4' -hexamethoxyflavanone on binding of LAG3 protein and MHC II protein
FIG. 2 curves of the binding of Compound 5,6,7,8,3',4' -hexamethoxyflavanone to LAG3 protein
Detailed Description
The present invention will be further described in detail with reference to the following examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The reagent materials used in the examples described below are commercially available unless otherwise specified.
Example one, extraction of Compounds
(1) The roots of Scutellaria baicalensis (Scutellaria baicalensis REHDERIANA DIELS) obtained from Gansu west of Gansu Province were dried in the shade and crushed to obtain 10kg of plant samples. It was immersed 3 times in 60L of methanol at room temperature for 7 days each. All the extracts were concentrated and combined to give 620g of crude extract, which was dissolved in hot distilled water and extracted sequentially with ethyl acetate and n-butanol.
(2) 100G of ethyl acetate extract is separated on macroporous resin, and methanol/water is used for gradient elution according to the volume ratio (v: v) of 30:70, 50:50, 80:20 and 100:0, so that the corresponding four parts of 30%,50%,80% and 100% of extract are obtained.
(3) 50G of the 80% fraction from step (2) was separated on an MCI column, gradient eluted with methanol/water (10:90-100:0, v: v) and 10 fractions (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%) were collected according to TLC detection analysis.
(4) 30G of the 60% fraction obtained in the step (3) is separated by normal phase silica gel, petroleum ether/acetone (3:1-1:3) is used as eluent, and 5 components, 6A-6E, are obtained by TLC detection and analysis.
(5) The fragment 6A (2 g) obtained in step (4) was purified using sephadex (LH-20) (CHCl 3: meOH, 1:1) as eluent to give compound (40 mg).
Compounds of formula (I) :1H NMR(300MHz,CDCl3δin ppm,Jin Hz):δH6.52(s,H-3),7.33(d,J=1.8Hz,H-2′),6.90(d,J=8.7Hz,H-5′),7.44(dd,J=8.7,1.8Hz,H-6′),3.86(s,5-OCH3),3.88(s,6-OCH3),4.02(s,7-OCH3),3.87(s,8-OCH3),4.01(s,3′-OCH3),3.99(s,4′-OCH3);13C NMR(75MHz,CDCl3):δC 160.7(C-2),106.5(C-3),177.2(C-4),143.8(C-5),137.7(C-6),151.3(C-7),147.6(C-8),148.7(C-9),114.7(C-10),123.6(C-1′),108.5(C-2′),149.2(C-3′),151.8(C-4′),111.2(C-5′),119.3(C-6′),62.1(5-OCH3),55.9(6-OCH3),61.9(7-OCH3),55.8(8-OCH3),61.8(3′-OCH3),61.4(4′-OCH3).
The structural identification proves that the compound is 5,6,7,8,3',4' -hexamethoxyflavanone, the structural formula is shown as formula (I), and the molecular formula is shown as the specification: c 21H22O8, molecular weight: 402.13, the characters are as follows: yellow solid, with CAS number 67549-69-3.
It should be noted that the extraction method described in the first embodiment is only one extraction method of the compound 5,6,7,8,3',4' -hexamethoxyflavanone, and the compound 5,6,7,8,3',4' -hexamethoxyflavanone may be obtained by other routes, such as purchase, synthesis, etc.
Example two, inhibition Activity of Compounds 5,6,7,8,3',4' -hexamethoxyflavanone on protein binding experiments
1. Experimental grouping
Positive control: 4 mu LTag-LAG 3,4 mu LTag2-MHC II, 5 mu L anti-Tag1-Tb 3+ and 5 mu L anti-Tag2-XL665, and 2 mu L dilutions
Negative control: 4 mu LTag-MHC II, 5 mu L anti-Tag1-Tb 3+ and 5 mu L anti-Tag2-XL665, and 6 mu L dilution
Blank control: mu.L of anti-Tag1-Tb 3+ and 10. Mu.L of diluent, and 5. Mu.L of detection buffer.
2. Experimental reagent and source
LAG3/MHC ii kits were all purchased from Cisbio.
Tag1-LAG3, tag2-MHC II, anti-Tag1-Tb 3+, anti-Tag2-XL665 and 2. Mu.L dilutions were all from the kit.
3. Experimental method
(1) The test compound 5,6,7,8,3',4' -hexamethoxyflavanone was dissolved using DMSO, and the test compound 5,6,7,8,3',4' -hexamethoxyflavanone was diluted using the dilution liquid prepared in the kit.
(2) Mu.L of the compound 5,6,7,8,3',4' -hexamethoxyflavanone mother liquor, 4 mu LTag-LAG 3 protein and 4 mu LMHC II protein were added to 96-well plates.
(3) Incubation was carried out at room temperature for 15 minutes, and then 5. Mu.L of anti-Tag1-Tb3 + and 5. Mu.L of anti-Tag2-XL665 (or a premix of 10. Mu.L of anti-Tag1-Tb3 + and 5. Mu.L of anti-Tag2-XL 665) were added and mixed well, at which time the final volume in each well was 20. Mu.L, keeping DMSO below 0.5% during the assay.
(4) Incubation was performed at room temperature for 1 hour to overnight, and specific emission signals at 665nm were detected using a homogeneous time resolved fluorescence (Homogeneous Time-resolved Fluorescence) detector.
Calculation formula of inhibition ratio of 5,6,7,8,3',4' -hexamethoxyflavanone to LAG3 protein and MHC ii binding:
Inhibition ratio = (positive control group 665nm fluorescent signal-experimental group 665nm fluorescent signal)/(positive control group 665nm fluorescent signal-blank group 665nm fluorescent signal)
4. Experimental results
TABLE 1 binding force of 5,6,7,8,3',4' -hexamethoxyflavanone with LAG3
The compound 5,6,7,8,3',4' -hexamethoxyflavanone has strong inhibition activity on the combination of LAG3 protein and MHC II protein, and the IC 50 value is 1.54 mu M.
In conclusion, the compound 5,6,7,8,3',4' -hexamethoxyflavanone of the invention can be used as LAG3 protein inhibitor with IC 50 value of 1.54 mu M for treating tumor,
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Furthermore, it should be understood that although the present disclosure describes embodiments, not every embodiment is provided with a separate embodiment, and that this description is provided for clarity only, and that the disclosure is not limited to the embodiments described in detail below, and that the embodiments described in the examples may be combined as appropriate to form other embodiments that will be apparent to those skilled in the art.
Claims (1)
1. The use of a compound 5,6,7,8,3',4' -hexamethoxyflavone as LAG3 protein inhibitor for non-diagnostic and non-therapeutic purposes, said compound 5,6,7,8,3',4' -hexamethoxyflavone being capable of inhibiting LAG3 protein binding to MHC ii protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210096008.7A CN114869877B (en) | 2022-01-26 | 2022-01-26 | Small molecule compound and application thereof as LAG3 protein inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210096008.7A CN114869877B (en) | 2022-01-26 | 2022-01-26 | Small molecule compound and application thereof as LAG3 protein inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114869877A CN114869877A (en) | 2022-08-09 |
CN114869877B true CN114869877B (en) | 2024-05-31 |
Family
ID=82667838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210096008.7A Active CN114869877B (en) | 2022-01-26 | 2022-01-26 | Small molecule compound and application thereof as LAG3 protein inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114869877B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110720039A (en) * | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Treatment of LAG-3 positive tumors |
CN113801084A (en) * | 2021-10-14 | 2021-12-17 | 三峡大学 | Polymethoxyflavone extracted from orange vinegar fermentation substrate sludge, and extraction method and application thereof |
-
2022
- 2022-01-26 CN CN202210096008.7A patent/CN114869877B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110720039A (en) * | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Treatment of LAG-3 positive tumors |
CN113801084A (en) * | 2021-10-14 | 2021-12-17 | 三峡大学 | Polymethoxyflavone extracted from orange vinegar fermentation substrate sludge, and extraction method and application thereof |
Non-Patent Citations (5)
Title |
---|
Cytotoxic Flavonoids from the Leaves and Twigs of Murraya tetramera;Chun-Xue You等;Molecules;第26卷(第1284期);第1-7页 * |
LAG3 (CD223) as a cancer immunotherapy target;Lawrence P. Andrews等;Immunological Reviews;第276卷;第80-96页 * |
Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells;Nipin Sp等;Int. J. Mol. Sci.;第22卷(第9843期);第1-20页 * |
Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways;Milad Ashrafizadeh等;Biomedicines;第8卷;第1-31页 * |
Recent study on the anticancer activity of nobiletin and its metabolites;Ke Lv等;J. Food Bioact.;第14卷;第53-59页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114869877A (en) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ferrigni et al. | Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae | |
CN104592242B (en) | Icotinib hydrochloride crystal forms, medicine composition and application | |
CN101928288B (en) | Small molecule compositions for binding to HSP90 | |
CN103204838B (en) | The synthesis of polyhydroxy Benzofurantone compound and its antitumor action | |
CN101213164B (en) | Aryl dihydro-naphthalene compounds, their preparation and their use as Akt inhibitor for the prevention and treatment of cancer | |
Arens et al. | Detection of pericine, a new CNS-active indole alkaloid from Picralima nitida cell suspension culture by opiate receptor binding studies | |
CN101321528A (en) | 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation | |
CN112300156B (en) | Marine-derived anti-tumor active compound and preparation method and application thereof | |
Li et al. | A new coumestan with immunosuppressive activities from Flemingia philippinensis | |
CN105884621A (en) | Sesquiterpenoids as well as preparation method and application thereof | |
CN110343116A (en) | A kind of Flos Chrysanthemi Indici extract and preparation method thereof and the application in preparation treatment medicine for nasopharyngeal | |
Zhang et al. | Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells | |
CN114869877B (en) | Small molecule compound and application thereof as LAG3 protein inhibitor | |
Zhang et al. | Cudraxanthone L inhibits gastric cancer by regulating the MAPK signalling and promoting FAS-mediated pathway | |
Zhou et al. | Diverse alkaloids from the aerial parts of Aconitum carmichaelii and antiproliferative activity of costemline via inhibiting SIRT1/ROCK1/P-STAT3 pathways | |
US10292972B1 (en) | Pharmaceutical composition for treating cancer and a method thereof | |
David et al. | Sesquiterpene lactones from Ambrosia artemisiaefolia (Asteraceae) | |
JPH10508611A (en) | Eliuserobin and its analogs | |
Güzelcan et al. | Synthesis of new derivatives of boehmeriasin A and their biological evaluation in liver cancer | |
CN113620912B (en) | Furanone compound and preparation method and application thereof | |
Henidi et al. | Design and synthesis of novel phenylaminopyrimidines with antiproliferative activity against colorectal cancer | |
Ya-Ming et al. | Solid tumor inhibitory and other constituents of Casimiroa tetrameria | |
CN112500409A (en) | Preparation method and application of marine alkaloid CDK2 inhibitor | |
CN101343274B (en) | Carbazoles alkaloid, preparation and application thereof | |
CN110698443A (en) | SHP2 small-molecule selective inhibitor and application thereof in preparation of anti-lung cancer drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |